Journal profile · Medicine-Hematology
HemaSphere
ISSN 2572-9241 · Wolters Kluwer Health · United States
HemaSphere: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 6.94; fully open access; APC about USD 2,880; median 94 days to acceptance (99 articles, last 24 months); acceptance rate 19% (journal website); 247 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
HemaSphere is published by Wolters Kluwer Health and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research and Lymphoma Diagnosis and Treatment, together about 33.8% of its articles. Its main subfields are Hematology and Genetics. (generated from OpenAlex topic counts and CAS ranking data)
HemaSphere is the official open access journal of the European Hematology Association (EHA). HemaSphere is a leading hematology journal publishing innovative basic, translational, and clinical research in all aspects of hematology. We are looking for strong studies that are very detailed and provide new, conclusive insight that is novel in the field. Biology studies should be based on relevant models and present clear, conclusive data. Observations without further confirmation, data on single cell lines, or studies without links to human hematology are unlikely to be considered for publication. Our priority for clinical research goes to results of prospective trials, new diagnostic methods, new drug development, mechanisms of therapy/therapy resistance, and related topics. Preliminary reports, underpowered studies, retrospective studies in fields where prospective studies are possible, and case reports/series are unlikely to be considered for publication. HemaSphere is guided by Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison. The Editors and Editorial Board of HemaSphere are international research and clinical leaders, representing a diverse range of hematologic expertise areas. Impact Factor and Citation Metrics HemaSphere is proud to have a 2024 Journal Impact Factor (JIF) of 14.6 (source: Journal Citation Reports, Clarivate). HemaSphere also has a Scopus 2024 CiteScore of 7.2. Indexing Information CAS: Chemical Abstracts Service (ACS) Current Contents: Clinical Medicine (Clarivate Analytics) Directory of Open Access Journals (DOAJ) Embase (Elsevier) Open Access Journal Index – OAJ (NSLC & CEPIEC) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier) All HemaSphere publications are indexed in PMC (PubMed Central).
From the journal's Aims & Scope
Research area (LetPub): Medicine-Hematology
Editor-in-chief Jan CoolsPublisher website
Editorial board by country: 2 in mainland China (about 2%); most named United Kingdom 13, United States 10, Germany 9, Italy 9, Netherlands 7 (88 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine12.8%
- Chronic Lymphocytic Leukemia ResearchMedicine11.6%
- Lymphoma Diagnosis and TreatmentMedicine9.5%
- Multiple Myeloma Research and TreatmentsMedicine7.4%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine6.7%
- Chronic Myeloid Leukemia TreatmentsMedicine6.7%
- CAR-T cell therapy researchMedicine6.3%
- Hemoglobinopathies and Related DisordersMedicine6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCEmbaseCASCurrent ContentsPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.94LetPub ·
- Impact factor (publisher)
- 11.3Publisher website ·
- Impact factor (publisher) 2025
- 11.3Publisher website ·
- CiteScore 2026-06
- 6.9LetPub ·
- CiteScore (publisher)
- 6.9Publisher website ·
- CiteScore (publisher) 2025
- 6.9Publisher website ·
- CiteScore (publisher) 2024
- 7.2Publisher website ·
- SJR 2026-06
- 2LetPub ·
- SNIP 2026-06
- 1.42LetPub ·
- h-index
- 53OpenAlex ·
- i10-index
- 483OpenAlex ·
- 2-year mean citedness
- 3.41OpenAlex ·
- Self-citation rate
- 2.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 116LetPub ·
- Articles per year (publisher) 2025
- 205Publisher website ·
- Downloads per year (publisher) 2025
- 529,305Publisher website ·
Articles by year OpenAlex count · 9,447 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 209 | 209 | 98 |
| 2025 | 247 | 247 | 884 |
| 2024 | 195 | 195 | 1,241 |
| 2023 | 2,917 | 2,917 | 3,854 |
| 2022 | 2,732 | 2,732 | 4,130 |
| 2021 | 162 | 162 | 2,681 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
94 daysMedian, submission to acceptance · P25–P75 59 days – 141 days
- Acceptance to online
- median 42 days (100 articles)
- Submission to online
- median 140 days
- Sample
- 99 articles with submission and acceptance dates (475 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 7 weeksLetPub ·
- Acceptance rate (publisher)
- 19%Publisher website ·
- Acceptance rate (publisher) 2025
- 19%Publisher website ·
- Submission to first decision
- 6 daysPublisher website ·
- Submission to first decision 2025
- 6 daysPublisher website ·
- Submission to acceptance 2025
- 103 daysPublisher website ·
- Acceptance to publication 2025
- 45 daysPublisher website ·
- Submission to publication (journal-reported)
- about 7 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,880 / GBP 2,130 / EUR 2,500 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,480 / EUR 2,150 / GBP 1,830 | — | — | |
| LetPub | EUR 1,269 / USD 1,350 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted13
- articleArticle 5000 250 10 100 Yes Articles should report detailed and conclusive studies with important contributions to the field.Length not stated
- case reportTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- commentComment 1000 No abstract 1 15 No Comments or remarks about recently published articles in HemaSphere can be submitted as a "Comment" to open a discussion or add…Length not stated
- editorialTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- guideline articleGuideline Article 5000 250 10 100 Yes Guideline Articles should be written by a broad international group of experts.Length not stated
- hemapolicyHemaPolicy 1200 No abstract 1 25 No HemaPolicy articles are written on invitation.Length not stated
- hematopicsHemaTopics 1200 No abstract 2 25 No HemaTopics articles are written by our own Scientific Editors.Length not stated
- letterTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- letters to the editorTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- opinionTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- perspectiveTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- review articleTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
- short reviewTypes of Manuscripts Type Text word count* (max) Abstract word count (max) Figures / tables (max) References (max) Supplement possible? Article 5000 250 10 100 …Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints
- Authorship Authorship
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Please include an overview of each author's contribution to this manuscript. You are welcome to use abbreviations for author names as you see fit. Review editorial standards and scroll down for a description of authorship criteria.
Source ↗Publisher website ·- Conflicts of interest Disclosures
Authors must declare all possible conflicts of interest in the metadata at submission, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. Any conflict of interests statement should not be included in the body of the manuscript. All sources …
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
This journal expects data sharing. Manuscripts must contain a data sharing statement on whether or not data is available, as outlined in the International Committee of Medical Journal Editors policy (http://www.icmje.org). A data sharing plan must be included in a trial’s registration for those that begin enrolling participants on or after January 1, 2019. Authors of secondary analyses using share…
Source ↗Publisher website ·- License & copyright Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Obtaining Permission to Reproduce Material. The corresponding author is responsible for obtaining written permission to reproduce the material "in …
Source ↗Publisher website ·- Open access Open Access
This journal is a Gold Open Access journal. Submissions will be subject to an APC if accepted and published in the journal. You can read more about APCs and whether you may be eligible for waivers or discounts, through your institution, funder, or a country waiver. For more information on this journal’s APCs and licensing policy, please visit the journal's Open Access page.
Source ↗Publisher website ·- Peer review Submission and Peer Review Process
HemaSphere does not charge submission fees. New submissions should be made via the Wiley Authors submission portal. You may check the status of your submission at any time by logging on to https://authors.wiley.com/dashboard and clicking the "My Submissions" button. For technical help with the submission system, please contact submissionhelp@wiley.com. Duplicate Publication Manuscripts are reviewe…
Source ↗Publisher website ·- Preprints Preprints
Please find the Wiley preprint policy here. This journal accepts articles previously published on preprint servers. You are requested to update any pre-publication versions with a link to the final published article, once applicable. You may also post the final published version of the article immediately after publication. This journal operates a double-anonymized peer review process. Authors are…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wolters Kluwer Health
- Country or region
- United States
- Language
- English
- ISSN
- 2572-9241
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about HemaSphere
What CAS zone is HemaSphere in?
In the 2025 upgraded edition of the CAS Journal Ranking, HemaSphere is in Zone 3 of Medicine, and in Zone 3 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of HemaSphere?
The latest impact factor listed by LetPub is 6.94; CiteScore 6.9, h-index 53.
How long does peer review take at HemaSphere?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 94 days (interquartile range 59–141 days); authors report an average review time of about 7 weeks; the journal's website gives an acceptance rate of 19% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of HemaSphere based?
Of the 88 board members whose country the journal's board page names, 2 (about 2%) are in mainland China; the countries named most often are United Kingdom (13), United States (10) and Germany (9). Counted from the institutions listed on the board page; for reference only.
Which databases index HemaSphere?
According to LetPub and DOAJ records, HemaSphere is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PMC, Embase, CAS and Current Contents; that list has not been checked against each database.
Is HemaSphere open access, and what is the APC?
HemaSphere is a fully open-access journal. APC about USD 2,880.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .